Savara Inc. Public Offering: Savara Inc. has completed an underwritten public offering of 28,452,381 shares of common stock at $4.20 per share, raising approximately $149.5 million in gross proceeds.
Warrants and Underwriters: The offering included pre-funded warrants for 7,142,857 shares at $4.199 each, with Jefferies, Piper Sandler, and Guggenheim Securities serving as joint book-running managers.
Regulatory Compliance: The securities were offered under an existing shelf registration statement filed with the SEC, with the final prospectus supplement filed on October 30, 2025.
Company Focus: Savara is a clinical stage biopharmaceutical company specializing in rare respiratory diseases, with its lead program, MOLBREEVI, in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 10.17 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 10.17 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.020
Low
9.00
Averages
10.17
High
11.00
Current: 6.020
Low
9.00
Averages
10.17
High
11.00
H.C. Wainwright
Andrew Fein
Buy
maintain
$8 -> $10
2025-12-23
Reason
H.C. Wainwright
Andrew Fein
Price Target
$8 -> $10
AI Analysis
2025-12-23
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on Savara to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted the application for Molbreevi with Fujifilm Diosynth as its drug substance manufacturer, the analyst tells investors in a research note. The firm believes Savara is increasingly well positioned ahead of a potential Molbreevi launch.
Oppenheimer
Oppenheimer
Outperform
maintain
$8 -> $9
2025-11-14
Reason
Oppenheimer
Oppenheimer
Price Target
$8 -> $9
2025-11-14
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Savara to $9 from $8 and keeps an Outperform rating on the shares. Ahead of December 2025 BLA submission for MOLBREEVI, the firm continues to see a more than $1B opportunity for MOLBREEVI in aPAP following recent updated claims data giving line of sight to at least 1,000 patients by launch with 750 already identified.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SVRA
Unlock Now
Citizens JMP
Jonathan Wolleben
Outperform
to
Outperform
downgrade
$11 -> $10
2025-11-13
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$11 -> $10
2025-11-13
downgrade
Outperform
to
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Savara to $10 from $11 and keeps an Outperform rating on the shares. Savara remains on track to resubmit its biologics license application for Molbreevi in December, with an MAA submission in the EU and UK expected in 1Q26, the analyst tells investors in a research note. The firm is impressed with management's execution on quickly resolving manufacturing deficiencies that prompted a complete response letter in May.
Citizens JMP
Outperform
maintain
$8 -> $11
2025-10-23
Reason
Citizens JMP
Price Target
$8 -> $11
2025-10-23
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Savara to $11 from $8 and keeps an Outperform rating on the shares. The firm's pulmonologist survey indicates high demand for Molbreevi. 60% of those surveyed want to use Molbreevi, which should translate to blockbuster sales, the analyst tells investors in a research note. Citizens says Savara remains on track to resubmit its application for Molbreevi in December.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
